Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis
Digestive Diseases and Sciences · 2025
DOI: 10.1007/s10620-024-08742-w ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Digestive Diseases and Sciences, 2025. Verfasst von Nicholas A Cumpian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary, Cholagogues and Choleretics. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Treatment for primary biliary cholangitis (PBC) was defined by its singular relationship with ursodeoxycholic acid (UDCA) for decades. However, nearly 40% of patients fail to achieve adequate biochemical response with UDCA, necessitating second-line therapies. AIMS: The aim of our review was to assess the efficacy and safety of second-line therapies for PBC from phase three trials. METHODS: We conducted a systematic review of PubMed, Medline, and ClinicalTrials.gov for published phase three trial data of second-line PBC therapies. RESULTS: Four phase three clinical trial evaluating obeticholic acid, bezafibrate, seladelpar, and elafibranor, were identified. All trials but one defined the treatment endpoints of an alkaline phosphatase (ALP) less than 1.67 times the upper limit of normal (ULN), a 15% decrease of ALP from baseline, and normal total bilirubin (TB) after 12 months. All therapies demonstrated statistically significant achievement of primary endpoints relative to placebo. Reduction in ALP from baseline ranged from 113 to 133.9 U/L (- 34.6% to - 50%) across all trials. Primary endpoint treatment differences relative to placebo ranged between 31 and 47%. ALP normalization rates were described for three treatments and varied between 15 and 67% in treatment cohorts,compared to 0% to 2% of placebo cohorts. Only elafibranor and seladelpar demonstrated significant reduction in total 5D itch scale scores. Discontinuation rates across studies ranged from 1 to 14% due to adverse effects. CONCLUSION: All reviewed therapies met their respective study endpoints. Effective second-line therapies area available and continue to receive long-term evaluation in patients with PBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA.
- Department of Medicine and Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- Department of Medicine and Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Ssaab@mednet.ucla.edu.
- Pfleger Liver Institute, UCLA Medical Center, 100 Medical Plaza, Suite 700, Los Angeles, CA, 90095, USA. Ssaab@mednet.ucla.edu.
Zitieren
APA
Cumpian, N. A., Choi, G., & Saab, S. (2025). Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08742-w
Vancouver
Cumpian NA, Choi G, Saab S. Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis. Digestive Diseases and Sciences. 2025. doi:10.1007/s10620-024-08742-w
BibTeX
@article{Cumpian2025,
author = {Cumpian, Nicholas A and Choi, Gina and Saab, Sammy},
title = {Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis},
journal = {Digestive Diseases and Sciences},
year = {2025},
doi = {10.1007/s10620-024-08742-w}
}
EUVIMED